Policy & Regulation
Quercis Pharma signs global licensing agreement for two patents with the Beth Israel Deaconess Medical Center
26 January 2021 -

Switzerland-based Quercis Pharma AG, a privately held biopharmaceutical company developing a set of advanced-phase clinical studies focused on the prevention of venous thromboembolism (VTE) in cancer patients, has signed an exclusive, global licensing agreement for two patents with the Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School, concentrating on modulation, risk reduction of thrombotic pathologies and thrombotic events in cancer patients, it was reported on Monday.

The patents are associated with the main pathways of thrombotic inhibitors, including P-selectin. They also relate to the transport of cancer cells in the blood and are likely to play a role in preventing and decreasing tumour metastases.

The terms of the transaction have not been revealed.

Login
Username:

Password: